Compare RR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | MYGN |
|---|---|---|
| Founded | 2016 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 583.6M | 481.6M |
| IPO Year | 2023 | 1996 |
| Metric | RR | MYGN |
|---|---|---|
| Price | $2.32 | $4.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $6.00 | ★ $7.64 |
| AVG Volume (30 Days) | ★ 8.8M | 1.6M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,045,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $78.28 | $5.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.99 | 2.33 |
| 52 Week Low | $1.69 | $3.76 |
| 52 Week High | $7.43 | $10.30 |
| Indicator | RR | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 40.01 |
| Support Level | $1.83 | $3.93 |
| Resistance Level | $2.33 | $5.63 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 6.00 | 16.43 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.